The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, ...

Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

NHS England has agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced its once-monthly PrEP ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that ...

Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, a key study of an Ultragenyx and Mereo drug ...

While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...